| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 346 | 0 | 637 | 400 | 695 | 0 | 32.043 |
| Total Income - EUR | 0 | 0 | 0 | 346 | 0 | 637 | 400 | 695 | 0 | 32.043 |
| Total Expenses - EUR | 2.655 | 3.948 | 4.044 | 62 | 0 | 0 | 60 | 74 | 90 | 4.647 |
| Gross Profit/Loss - EUR | -2.655 | -3.948 | -4.044 | 284 | 0 | 637 | 340 | 621 | -90 | 27.396 |
| Net Profit/Loss - EUR | -2.655 | -3.948 | -4.044 | 274 | 0 | 618 | 328 | 600 | -90 | 23.100 |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Nanobiomed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 20 | 37 | 139 | 491 | 481 | 1.109 | 1.445 | 2.055 | 1.958 | 27.673 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 144 | 488 | 478 | 1.106 | 628 | 630 | 629 | 0 |
| Cash | 20 | 37 | -5 | 3 | 3 | 3 | 817 | 1.425 | 1.330 | 27.673 |
| Shareholders Funds | -2.610 | -6.531 | -10.465 | -9.999 | -9.805 | -9.001 | -8.473 | -7.899 | -7.966 | 14.500 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 2.629 | 6.569 | 10.604 | 10.490 | 10.287 | 10.110 | 9.918 | 9.954 | 9.924 | 13.173 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2660 - 2660" | |||||||||
| CAEN Financial Year |
2660
|
|||||||||
Comments - Nanobiomed Srl